Evidence map›Paper›PMID 41542284›Full record

Observational studyCardiovascular therapeutics2026

Low-Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real-World Study in China.

Wenlong Yang, Hui Shi, Rebecca Suchi Chang, Yin Zhang, A Jixiang, Chunyu Wu, Juying Qian, Junbo Ge, Shuning Zhang

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenlong YangDepartment of Cardiology, Zhongshan Hospital, and Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China, fudan.edu.cn.
Hui ShiDepartment of Cardiology, Zhongshan Hospital, and Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China, fudan.edu.cn.
Rebecca Suchi ChangDepartment of Cardiology, Zhongshan Hospital, and Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China, fudan.edu.cn.ORCID https://orcid.org/0000-0002-2352-6641
Yin ZhangDepartment of Cardiology, Zhongshan Hospital, and Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China, fudan.edu.cn.ORCID https://orcid.org/0000-0001-7800-8828
A JixiangDepartment of Cardiology, Zhongshan Hospital, and Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China, fudan.edu.cn.
Chunyu WuDepartment of Cardiology, Zhongshan Hospital, and Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China, fudan.edu.cn.
Juying QianDepartment of Cardiology, Zhongshan Hospital, and Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China, fudan.edu.cn.ORCID https://orcid.org/0000-0002-7512-3692
Junbo GeDepartment of Cardiology, Zhongshan Hospital, and Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China, fudan.edu.cn.ORCID https://orcid.org/0000-0002-9360-7332
Shuning ZhangDepartment of Cardiology, Zhongshan Hospital, and Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China, fudan.edu.cn.ORCID https://orcid.org/0000-0003-0694-6553

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: To evaluate the real-world efficacy and safety of low-dose (2.5 mg) mavacamten initiation in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Methods and Results: This single-center observational study (Zhongshan Hospital, China; Oct 2024-Apr 2025) enrolled 72 symptomatic oHCM patients (NYHA II/III, LVEF ≥ 55%, resting/Valsalva-provoked LVOT gradient [LVOTG] ≥ 30 mmHg). All patients initiated mavacamten 2.5 mg once daily. Doses were adjusted at Weeks 4, 8, and 12 based on LVEF and LVOTG. Primary outcomes were changes in resting/provoked LVOTG, NT-proBNP, and NYHA class at Week 12. Safety outcomes included LVEF < 50%, cardiac hospitalization, and death.Significant reductions from baseline to Week 12 were observed: Resting LVOTG (52.4 ± 28.7 to 32.1 ± 23.1 mmHg, Conclusion: In this first Chinese real-world study, initiating mavacamten at 2.5 mg significantly improved haemodynamics (LVOTG), biomarkers (NT-proBNP), and functional status (NYHA) in oHCM patients over 12 weeks with an excellent safety profile. Greater haemodynamic efficacy was observed in classic HCM and high-baseline-gradient patients. Escalation to 5 mg provided additional benefit. Mavacamten is an effective and safe therapy for oHCM in this Asian population.

Indexed as

Cardiomyopathy, HypertrophicCardiovascular AgentsUracilVentricular Function, LeftAdultAgedBenzylaminesBiomarkersChinaFemaleHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsRecovery of FunctionBenzylaminesBiomarkersCardiovascular AgentsMYK-461Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Uracilleft ventricular outflow tract obstructionmavacamtenobstructive hypertrophic cardiomyopathy

Identifiers

PMID41542284
PMCPMC12801204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.